<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04648254</url>
  </required_header>
  <id_info>
    <org_study_id>Q702-ONC-P1-US001</org_study_id>
    <nct_id>NCT04648254</nct_id>
  </id_info>
  <brief_title>Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor</brief_title>
  <official_title>A Phase 1, Multicenter, Open-label, Dose- Escalation, Safety, Pharmacodynamic, Pharmacokinetic Study of Q702 With a Cohort Expansion at the RP2D in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Qurient Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Qurient Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1, open-label, multicenter, dose-escalation, safety, tolerability,&#xD;
      pharmacokinetic and pharmacodynamic study with cohort expansion at the RP2D to evaluate&#xD;
      safety and anti- tumor activity of Q702 administered orally.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 18, 2020</start_date>
  <completion_date type="Anticipated">November 18, 2023</completion_date>
  <primary_completion_date type="Anticipated">July 18, 2023</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum tolerated dose (MTD), the dose limiting toxicities (DLT) and the safety profile of Q702</measure>
    <time_frame>28 days of cycle 1</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in the area under curve (AUC) of Q702</measure>
    <time_frame>Cycle 1, Days 1,2,8,15,21,22; Cycle 2, Days 1,8,15,22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the maximum plasma concentration (Cmax) of Q702</measure>
    <time_frame>Cycle 1, Days 1,2,8,15,21,22; Cycle 2, Days 1,8,15,22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the time of maximum plasma concentration (Tmax) of Q702</measure>
    <time_frame>Cycle 1, Days 1,2,8,15,21,22; Cycle 2, Days 1,8,15,22</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response using RECIST version 1.1 throughout study</measure>
    <time_frame>Baseline up to approximately 2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">78</enrollment>
  <condition>Solid Tumor</condition>
  <condition>Advanced Cancer</condition>
  <condition>Metastatic Cancer</condition>
  <arm_group>
    <arm_group_label>Dose escalation (Q702)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive escalating doses of Q702</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Q702</intervention_name>
    <description>The study drug Q702 will be administered once daily by mouth on Days 1 through 7 and Days 15 through 21 of every treatment cycle.</description>
    <arm_group_label>Dose escalation (Q702)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with histologically or cytologically confirmed advanced or metastatic solid&#xD;
             tumors, that have progressed following standard of care therapy or for which there is&#xD;
             no standard therapy which confers clinical benefit&#xD;
&#xD;
          -  Measurable disease per RECIST v 1.1&#xD;
&#xD;
          -  ECOG performance status 0 or 1&#xD;
&#xD;
          -  Life expectancy of at least 3 months&#xD;
&#xD;
          -  Age â‰¥ 18 years&#xD;
&#xD;
          -  Signed, written IRB-approved informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  New York Heart Association Class III or IV cardiac disease, or myocardial infarction,&#xD;
             severe unstable angina, coronary/peripheral artery bypass graft, congestive heart&#xD;
             failure within the past 6 months&#xD;
&#xD;
          -  Have a corrected QT interval (using Fridericia's correction formula) (QTcF) of &gt;470&#xD;
             msec (females) and &gt;450 msec (males)&#xD;
&#xD;
          -  Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic&#xD;
             therapy&#xD;
&#xD;
          -  Active, poorly controlled autoimmune or inflammatory diseases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Qurient Clinical Trial Information</last_name>
    <phone>+82-31-8060-1610</phone>
    <phone_ext>(KST)</phone_ext>
    <email>clinicaltrial_info@qurient.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Southern California</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>See Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>See Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>See Central Contact</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Atlantic Health System Hospital</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>See Central Contact</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>November 19, 2020</study_first_submitted>
  <study_first_submitted_qc>November 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 1, 2020</study_first_posted>
  <last_update_submitted>July 29, 2021</last_update_submitted>
  <last_update_submitted_qc>July 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

